Mubadala Bio has launched the UAE’s first locally manufactured hemodialysis concentrate solutions through its Abu Dhabi-based subsidiary, Wellpharma, marking a significant milestone in the country’s pharmaceutical manufacturing sector.
The launch includes eight hospital-grade hemodialysis solutions designed for patients with kidney failure, supporting dialysis procedures by helping remove waste products and maintain electrolyte balance. Local production is expected to strengthen the supply of essential therapies for hospitals and dialysis centres across the UAE.
Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio said, “Since the launch of Mubadala Bio in 2025, we have continued to make significant progress in advancing capabilities across the life sciences sector. The introduction of locally manufactured hemodialysis solutions marks an important milestone, given the critical role these products play within the healthcare ecosystem. We remain committed to supporting the continued development of strategic healthcare capabilities and strengthening access to essential medical products”
Click here to join our WhatsApp channel here
Dr. Essam Mohamed, Group CEO, Mubadala Bio, said, “The launch of the new hemodialysis solutions marks an important milestone for us as well as for the wider healthcare sector in the UAE. By producing them locally, we are ensuring more consistent supply of critical therapies for patients who depend on dialysis treatments while reinforcing our capabilities in the production of essential and specialized hospital-based therapies.”
Also read: New Research Collaboration Aims to Advance Personalized Cancer Treatment
Hamad Almarzooqi, Group Deputy CEO, Mubadala Bio, stated, “Strengthening local manufacturing capabilities is central to supporting Abu Dhabi and the UAE’s ambition to become a leading hub for life sciences. Building a globally competitive sector requires strong domestic capabilities across the pharmaceutical value chain. The launch of locally manufactured hemodialysis solutions marks an important step in advancing these capabilities.”
Mubadala Bio said the initiative supports the UAE’s ambitions to expand life sciences manufacturing, improve healthcare resilience, and enhance access to critical medical products. The announcement comes as chronic kidney disease continues to rise globally, driven largely by increasing rates of diabetes, hypertension, and obesity.
